A Multicenter, Single-Arm Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Status
Active
Cancer Type
Multiple Myeloma
Trial Phase
Phase IV
Eligibility
18 and over, Male and Female
Study Type
Treatment
NCD ID
NCT00179647
Protocol IDs
CC-5013-MM-016 (primary)
FHCRC-2068.00
CELGENE-CC-5013-MM-016
Study Sponsor
Celgene Corporation

Summary

Subjects who qualify for participation will receive lenalidomide plus high dose dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for multiple myeloma.